NEW YORK (CNNMoney) - Sanofi-Aventis said on Wednesday that buy drugs for Genzyme 20.1 billion U.S. dollars in cash, plus payments contingent on the success of some of Genzyme.
The French pharmaceutical giant said that the companies pay $ 74 per share for the, Massachusetts, Cambridge Biotechnology. Genzyme (GENZ, Fortune 500) shares closed Tuesday at $ 74.30 each. The stock was traded weeks in a range between about $ 72 and $ 74.50 over the past 52nd
The long awaited merger, which received approval from antitrust regulators in the U.S. and Europe, is planned for early 2011 in the vicinity of the second quarter.
Under the agreement, Sanofi (SA) each shareholder Genzyme will also award a "Contingent Value Right" - or CVR - for each share they own. The TRC, which eventually become publicly traded entitle the holder to payments cash if the drug Genzyme achieve certain goals.
"This transaction aventis new growth platform for Sanofi useful, and expand our presence in biotechnology," said Christopher Viehbacher, Director General of the French pharmaceutical group.
Viehbacher said that the CVR was used as a bridge high value "between the two companies, and it rewards two Genzyme and Sanofi-Aventis shareholders."
Shares of Genzyme (GENZ, Fortune 500) edged higher in pre-market trade of about 1%, while the U.S. list from Sanofi (SNY) rose nearly 1.4%. 
0 komentar:
Posting Komentar